Clinically Validated Genotype Analysis

Brun-Vézinet F. , Costagliola D. , Khaled M.A. , Calvez V. , Clavel F. , Clotet B. , Haubrich R. , Kempf D. , King M. , Kuritzkes D. , Lanier R. , Miller M. , Miller V. , Phillips A. , Pillay D. , Schapiro J. , Scott J. , Shafer R. , Zazzi M. , Zolopa A. , & DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antiviral Therapy 2004, 9: 465–478.

Brun-Vézinet F. , Descamps D. , Ruffault A. , Masquelier B. , Calvez V. , Peytavin G. , Telles F. , Morand-Joubert L. , Meynard J.L. , Vray M. , & Costagliola D. ; Narval (A.N.R.S. 088) Study group. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003, 17: 1795–1802.

Marcelin A.G. , Flandre P. , Pavie J. , Schmidely N. , Wirden M. , Lada O. , Chiche D. , Bernard M.C. , Molina J.M. , & Calvez V. New genotypic score comprising mutations impacting negatively and positively the virological response to didanosine in treatment-experienced patients from the randomized didanosine add on Jaguar study. Antiviral Therapy 2004, 9: S146.

Descamps D. , Flandre P. , Joly V. , Meiffredy V. , Peytavin G. , Izopet J. , Tamalet C. , Zeng A-F , Harel M. , Lastère S. , Aboulker J.P. , Yéni P. , & Brun-Vézinet F. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. Journal of Acquired Immune Deficiency Syndromes 31: 464–471.